Press Room

CPHI Frankfurt 2025

Start
Tuesday, October 28, 2025
End
Thursday, October 30, 2025
Location: Frankfurt, Germany
Booth Number: 5.1C48

Hovione is exhibiting at CPHI Frankfurt 2025, one of the most relevant tradeshows for the pharma industry, bringing together leading professionals from the entire pharmaceutical supply chain to network, learn and conduct vital face-to-face business.

Meet the Hovione team at booth # 5.1C48 

This is the perfect opportunity to speak with our experts and learn how Hovione can deliver your entire project from one site, giving you the benefit of compressed timelines, seamless project management and knowledge, and increased sustainability.

Get to know more about our Innovative Platforms
At Hovione we have a reputation for transforming nascent technologies into large-scale GMP-compliant platforms by building strategic partnerships with our customers and technology partners. We look forward to seeing you to share some exciting news.
 

Schedule a meeting today.

schedule a meeting

 

Also in the Press Room

See All

The global inhalation contract development and manufacturing organization (CDMO) market is projected to grow from USD 9.13 billion in 2025 to USD 16.68 billion by 2035, reflecting a compound annual growth rate (CAGR) of 5.7% during the forecast period. This growth is driven by the increasing prevalence of respiratory diseases, advancements in inhalation drug delivery technologies, and the rising demand for outsourced manufacturing services in the pharmaceutical industry. The inhalation CDMO market has emerged as a pivotal segment in the pharmaceutical contract development and manufacturing industry. With a rising demand for inhaled therapies for conditions like asthma, COPD, and cystic fibrosis, companies are increasingly outsourcing drug development and production to specialized partners. Inhalation CDMO services cater to both large pharmaceutical corporations and small biotech firms, offering expertise in formulation, device compatibility, regulatory support, and scale-up manufacturing. This market is gaining traction due to the complexity of inhalation drug delivery, which often requires niche technical capabilities and specialized equipment. Outsourcing to an inhalation CDMO allows drug developers to reduce time-to-market while ensuring quality and compliance with global standards. (...) Top Companies Several players dominate the inhalation CDMO market through technological expertise, global reach, and service portfolio diversity: (...) Hovione – Offers particle engineering and inhalation development, with a focus on dry powder inhalers. (...) These companies are continually investing in facilities, talent, and technology to meet evolving customer needs in the inhalation CDMO market.   Read the full article on Pharmiweb.com        

Press Clipping

Inhalation CDMO Market Growth Analysis & Forecast 2025 to 2035

Jun 25, 2025